ASLAN PHARMACEU/ADR (NASDAQ:ASLN) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Thursday, reports.

According to Zacks, “ASLAN Pharmaceuticals Limited operates as a clinical-stage biotechnology company. It develops drugs, medicines and novel therapeutics for the treatment of patients with oncology, respiratory and inflammatory diseases. The company’s product portfolio includes Varlitinib, ASLAN004, ASLAN002 and ASLAN003 both are in clinical stage. ASLAN Pharmaceuticals Limited is based in Singapore. “

Other research analysts also recently issued research reports about the company. ValuEngine raised ASLAN PHARMACEU/ADR from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. HC Wainwright set a $9.00 target price on ASLAN PHARMACEU/ADR and gave the stock a “buy” rating in a report on Wednesday, June 5th.

NASDAQ ASLN traded down $0.11 during mid-day trading on Thursday, reaching $2.62. 100 shares of the company’s stock traded hands, compared to its average volume of 6,717. ASLAN PHARMACEU/ADR has a 1-year low of $2.51 and a 1-year high of $8.50. The firm’s fifty day simple moving average is $3.18. The stock has a market capitalization of $86.47 million, a P/E ratio of -1.87 and a beta of 2.11.


ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, engages in the development of drugs for prevalent cancers. It targets diseases that are prevalent in Asia, and orphan indications in the United States and Europe. The company's lead program, varlitinib, is a reversible small molecule pan-human epidermal growth factor receptor, or pan-HER, inhibitor that targets the human epidermal growth factor receptors HER1, HER2, and HER4.

See Also: If I purchase shares through a brokerage account, am I the holder of record?

Get a free copy of the Zacks research report on ASLAN PHARMACEU/ADR (ASLN)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for ASLAN PHARMACEU/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASLAN PHARMACEU/ADR and related companies with's FREE daily email newsletter.